Millions of Americans are expected to test for Alzheimer’s disease – some with at-home DNA test kits, others at labs — as new drugs for early Alzheimer’s, from partners Eisai and Biogen and Eli Lilly, usher in sweeping changes in treatment https://t.co/D1Ny08kJSN https://t.co/JgfEBUurn0
@Reuters
US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/sx3nKxLoYv https://t.co/wxL63AqsHx
@Reuters
Pfizer, Biogen among hundreds of US drugmakers calling for abortion pill ruling reversal https://t.co/nKnJKMfnHr https://t.co/yjm0WBw4GW
@Reuters
US FDA advisers to weigh full approval for Eisai-Biogen's Alzheimer's drug https://t.co/MysxC06M8V https://t.co/jxvX3Sw1y5
@Reuters
Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/eRoU2JxunD https://t.co/VAzT0W4iCb
@Reuters
Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Ym1X51nVBV https://t.co/9NTKMbzI1r
@Reuters
Eisai, Biogen say FDA grants priority review for Alzheimer's drug Lecanemab https://t.co/Bysx8mHeA4 https://t.co/bpjbjrlj87
@Reuters
Eisai, Biogen say Alzheimer's drug Lecanemab getting priority review in China https://t.co/8L0q1rOVxR https://t.co/L0KELgN969
@Reuters
Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/Fyg7ni9vv2 https://t.co/nPYonFlBKc
@Reuters
Biogen CEO bets on Alzheimer's drug, pipeline to return to growth https://t.co/GORyQxXcGd https://t.co/j4pNpDagY6
@Reuters
Biogen sees modest 2023 revenue from Alzheimer's disease drug https://t.co/XL1BwDKqTw https://t.co/uqdedtLHPw
@Reuters
Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/Wh8Tcs5azk https://t.co/5J5pZ9use9
@Reuters
Japan gives priority review status to Alzheimer's drug developed by Eisai, Biogen https://t.co/kTrEVHePch https://t.co/8oM6hrjRR5
@Reuters
Japan grants priority review status to Alzheimer's treatment from Eisai-Biogen https://t.co/wRxWzvIfq7 https://t.co/GrwduIAOfK
@Reuters
EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/JiSVeEebG6 https://t.co/5R3pEbciD4
@Reuters
EU regulator accepts for review Alzheimer's treatment from Eisai-Biogen https://t.co/15Wmhb3k6S https://t.co/Slfhelg0Bd
@Reuters
Eli Lilly Alzheimer's drug setback extends rival Biogen's lead https://t.co/8t1jxrKT4a https://t.co/k2Rqhi2hri